TME Pharma Announces Positive 15-month Survival Data From GLORIA Expansion Arm Evaluating NOX-A12 in Combination With Radiotherapy and Bevacizumab in Glioblastoma
83% of glioblastoma patients remain alive after 15 months on study, unchanged from the 14-month survival update 15-month…